Approval from the office of European Directorate - EDOM Approval for new product Rivaroxaban API, USFDA DMF Clearances.

Code BSE: 524212 NSE:

European Directorate for the Quality of Medicines and Healthcare (EDQM) for new product Rivaroxaban API recently which will enable to meet customer demand of EU and other countries accepting CEP. Company also received DMF clearance for Paraxetine HCI and for Metformin HCI from the office of USFDA while ANDA review for multiple customers.